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effective intervention. Flaws in other studies related to
the identification and measurement of costs, and to the
extrapolation of benefits. Overall there was a range in the
estimates of cost-effectiveness. For example, Messori et al
(1999) calculated the incremental cost per life year gained
to be approximately £41,000, whereas analysis by Tava-
koli, et al. (1999) used Markov modeling to incorporate
the importance of implications on quality of life in the re-
maining months. This methodology revealed that the
incremental cost per life year gained was £8,587, and
therefore identified riluzole as a cost-effective therapy.
CONCLUSION: Clear presentation and use of perspec-
tive and relevant disease end-points are vital in economic
evaluation to avoid paradoxes in results of studies assess-
ing similar interventions. For therapies such as riluzole,
where length of life and quality of life are key variables,
different end-points can provide contradictory results.
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OBJECTIVES: To build an economic model estimating
the costs of care for chest pain in migraine patients when
treated with almotriptan instead of sumatriptan. METH-
ODS: We conducted a population-based retrospective co-
hort study from the MEDSTAT Marketscan database.
Patients were continuously enrolled for any two consecu-
tive years between 1996 and 1998 and had a first pre-
scription for oral sumatriptan between July 1, 1996 and
June 30, 1998. Exclusion criteria included contraindica-
tions or risk factors for coronary artery disease. The
baseline and treatment periods were defined as five
months before and after the date of the first prescription
minus 15 days (since most patients receive samples). Pa-
tients with chest pain-related diagnoses and procedures
were compared between periods using the McNemar test.
The cost of chest pain-related care was used to build a
model estimating costs based on rates of chest pain from
clinical trials. RESULTS: Of 1,759 patients meeting in-
clusion criteria, 369 were excluded. The final cohort of
1,390 migraine patients showed a statistically significant
increase in the number experiencing chest pain after
treatment with sumatriptan (compared to the baseline pe-
riod) from 110 to 158 (p  0.003), a 43.6% increase. As-
sociated costs increased from $22,713 to $30,234. The
model estimated annual cost savings of $11,215 per
1,000 patients for migraine treated with almotriptan in-
stead of sumatriptan due to lower rates of chest pain
(0.3% vs. 2.2%, p  0.004). CONCLUSIONS: Direct
medical cost savings are predicted for health plans from
migraine patients switched from sumatriptan to almo-
triptan based on the lower rate of chest pain.
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OBJECTIVES: To examine the difference between the
Japanese versions of the Health Utilities Index (HUI)
Mark2 and the HUI Mark3 scores of patients with Alz-
heimer’s Disease (AD) in order to undertake the pharma-
coeconomic evaluation of AD drugs. METHODS: We
conducted a cross-sectional study of AD patients at four
sites (three in outpatient and one in institutional settings)
using the combined HUI2/HUI3 questionnaire. For those
who were not able to make self-evaluations, proxy evalu-
ations were made by caregivers in outpatient settings and
by the nursing staff in institutional settings. Severity of
dementia was measured by Clinical Dementia Rating
(CDR). RESULTS: With the HUI2, the mean (SD) utility
scores of the 63 outpatients with mild AD (n  19), mod-
erate AD (n  29), and severe AD (n  12) were
0.61(0.16), 0.50(0.25), 0.38(0.18), respectively. The cor-
responding scores with HUI3 were 0.33(0.23), 0.17(0.29),
and 0.02(0.25), respectively. For inpatient (n  12), it
was 0.37(0.21) for those with severe AD (n  10) with
the HUI2, and 0.04 (0.20) with the HUI3. The single
scores for each attribute of the HUI2 and 3 tended to de-
crease as the CDR level became more severe. CONCLU-
SIONS: Compared with the HUI2, the HUI3 yields sig-
nificantly lower global utility scores for patients with
AD. Based on our results, there appears to be a need to
further evaluate the validity of the HUI2 and HUI3.
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OBJECTIVE: To evaluate the pharmacoeconomics of
mitoxantrone (m) therapy in patients with progressive-
relapsing and secondary-progressive multiple sclerosis
(MS). METHODS: The MIMS trial showed that m im-
proves several outcomes in patients with progressive-
relapsing and secondary-progressive multiple sclerosis
(MS). Patients receiving m 12 mg/m2 every three months
had fewer relapses and hospitalizations, less progression
of neurologic disability, and improved quality of life and
functionality. A pharmacoeconomic analysis was under-
taken to compare resource consumption in the m and
placebo (p) groups. Major cost drivers were identified as
follows: drug therapy, including acquisition, administra-
tion, and monitoring (primarily m, IV corticosteroids,
and antibiotics); hospitalizations (5 days/occurrence);
physician visits (1/relapse); days lost from work (2/docu-
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mented relapse, 3 additional for relapse requiring IV cor-
ticosteroids, and 7/hospitalization). Standard costs were
assigned as follows: m ($1000/cycle); IV corticosteroids
used to treat relapses ($1250/occurrence); antibiotics
used to treat infections ($300/occurrence); hospitaliza-
tions ($1850/day); physician visits ($100/occurrence);
wages ($160/day). RESULTS: A cost-minimization anal-
ysis was done and the cost per patient per year was found
to be as follows: m therapy (m  $4000, p  $0); IV cor-
ticosteroid therapy (m  $250, p  $750); antibiotic
therapy (m  $96, p  $39); hospitalization (m 
$1850, p  $3145); physician visits (m  $40, p 
$100); lost wages (m  $448, p  $989). The total an-
nual cost per patient was $6684 in the m group and
$5023 in the p group. The annual cost of m ($4000) was
substantially offset by a reduction in other costs associ-
ated with p for a total annual incremental m cost of
$1661. CONCLUSIONS: MS is a chronic, debilitating
disease associated with considerable costs. Pharmacoeco-
nomic analyses suggest that m compares favorably with
other disease-modifying therapies for MS. Additional
data will be presented using remaining direct and indirect
cost drivers. The results of cost-effectiveness analyses in-
corporating patient outcome measures will also be pre-
sented.
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OBJECTIVE: GRIM 200 is an epidemiology survey on
migraine that was performed in France in 2000, ten years
after the first one (GRIM). The goal of this study was to
estimate the evolution of epidemiological data since ten
years, and to assess the impact of triptans on the disease
management and social repercussions of migraine.
METHODS: The survey was carried out by I.S.L, a na-
tional institute, on a representative sample of 10,585 sub-
jects in France aged 15 years and older according to the
quota method. There were 2 successive home interviews.
Persons suffering from headache were selected during the
first interview, or screening. They were then contacted
for a second interview with a validated questionnaire for
diagnosis of migraine. This questionnaire was the same
used in 1989 with supplementary questions concerning
triptans. RESULTS: We found a 8.2% prevalence of cer-
tain migraines (1-1 and 1-2 IHS) and a 17.3% prevalence
of certain migraines and migraine disorder (1-7 IHS).
Only 5.65% of headache sufferers (n  1486) were
treated by triptans. Of the 5.65% of patients using trip-
tans, we found 4.23% were migraine sufferers, 0.2% had
tension-type headache and 1.2% had chronic daily head-
ache. We found that 2.96% of the general population
were chronic daily headache patients (n  152). Of these,
18 patients were triptans abusers (11.8%). CONCLU-
SION: This study confirmed that triptans use by migraine
patients is very low in France in general population.
Overuse of triptans seems to be low in comparison with
other drugs.
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